EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence and Significance of AGR2 Expression in Human Cancer

Nina Schraps iD, Jacob Constantin Port, Anne Menz, Florian Viehweger, Seyma Büyücek iD, David Dum, Ria Schlichter, Andrea Hinsch, Christoph Fraune, Christian Bernreuther, Martina Kluth, Claudia Hube-Magg und 20 weitere

Cancer Medicine · 2024-11 · 13 (21)

DOI: 10.1002/cam4.70407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 12.11.2024. Verfasst von Nina Schraps und 31 weiteren Autor:innen. Beteiligte Einrichtung: General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Mucoproteins, Oncogene Proteins, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backround Anterior gradient 2 (AGR2) is a resident endoplasmic reticulum (ER) protein with a vital role in embryonal development, mucus maturation, tissue regeneration, and wound healing.

Methods

To determine the prevalence and clinical significance of AGR2 expression in cancer, a tissue microarray containing 14,966 tumors from 134 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry (IHC).

Results

AGR2 positivity was found in 103 of 134 tumor categories, and 83 tumor categories contained at least one strongly positive case. AGR2 expression was most frequently seen in tumors of the female genital tract, particularly adenocarcinomas (up to 100%), various breast cancer subtypes (57.1%–100%), urothelial carcinoma (74.6%–100%), adenocarcinomas of the upper and lower gastrointestinal tract (93.6%–99.6%), and pancreaticobiliary cancers (65.2%–98.2%). AGR2 positivity was slightly less common in squamous cell carcinomas (46.4%–77.3%) and mainly absent in mesenchymal and lymphoid tumors. While AGR2 expression was only weak or absent in the normal thyroid, it was moderate to strong in 46.0% of adenomas, 52.8% of follicular carcinomas, and 81.8% of papillary carcinomas of the thyroid. High AGR2 expression was strongly linked to poor ISUP ( p < 0.0001), Fuhrman ( p < 0.0001), and Thoenes ( p < 0.0001) grades as well as advanced pT stage ( p = 0.0035) in clear cell renal cell carcinoma (ccRCC). Low AGR2 expression was associated with high BRE grade in breast cancer ( p = 0.0049), nodal metastasis ( p = 0.0275) and RAS mutation ( p = 0.0136) in colorectal cancer, nodal metastasis ( p = 0.0482) in endometrioid endometrial carcinoma, high grade in noninvasive urothelial carcinoma ( p = 0.0003), and invasive tumor growth in urothelial carcinoma ( p < 0.0001).

Conclusions

It is concluded that AGR2 expression occurs in a broad range of different tumor entities and that AGR2 assessment may serve as a diagnostic aid for the distinction of thyroidal neoplasms and as a prognostic marker in various cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucoproteinsOncogene ProteinsNeoplasmsBiomarkers, TumorHumansFemaleProteinsMaleImmunohistochemistryTissue Array AnalysisPrognosisPrevalence

Substanzen

MucoproteinsAGR2 protein, humanOncogene ProteinsBiomarkers, TumorProteins

Autor:innen und Institutionen

  • General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany.
  • Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany.

ORCID-Profile: Nina Schraps, Seyma Büyücek, Ronald Simon

Zitieren

APA

Schraps, N., Port, J. C., Menz, A., Viehweger, F., Büyücek, S., Dum, D., Schlichter, R., Hinsch, A., Fraune, C., Bernreuther, C., Kluth, M., Hube-Magg, C., Möller, K., Reiswich, V., Luebke, A. M., Lebok, P., Weidemann, S., Sauter, G., Lennartz, M., …, & Lutz, F. (2024). Prevalence and Significance of AGR2 Expression in Human Cancer. Cancer Medicine, 13(21). https://doi.org/10.1002/cam4.70407

Vancouver

Schraps N, Port JC, Menz A, Viehweger F, Büyücek S, Dum D, et al. Prevalence and Significance of AGR2 Expression in Human Cancer. Cancer Medicine. 2024;13(21). doi:10.1002/cam4.70407

BibTeX
@article{Schraps2024,
  author = {Schraps, Nina and Port, Jacob Constantin and Menz, Anne and Viehweger, Florian and Büyücek, Seyma and Dum, David and Schlichter, Ria and Hinsch, Andrea and Fraune, Christoph and Bernreuther, Christian and Kluth, Martina and Hube-Magg, Claudia and Möller, Katharina and Reiswich, Viktor and Luebke, Andreas M and Lebok, Patrick and Weidemann, Sören and Sauter, Guido and Lennartz, Maximilian and Jacobsen, Frank and Clauditz, Till S and Marx, Andreas H and Simon, Ronald and Steurer, Stefan and Mercanoglu, Baris and Melling, Nathaniel and Hackert, Thilo and Burandt, Eike and Gorbokon, Natalia and Minner, Sarah and Krech, Till and Lutz, Florian},
  title = {Prevalence and Significance of AGR2 Expression in Human Cancer},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {21},
  doi = {10.1002/cam4.70407}
}
Kostenlos starten →